Company Encyclopedia
View More
name
HENGRUI PHARMA
01276.HK
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes drugs in China and internationally. The company develops antineoplastic drugs; surgery medications; medicines for oncology, autoimmune diseases, pain management, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, and ophthalmology, etc.; analgesia and anesthesia products; and contrast agents. It is also involved in technical consulting; training; investment advisory; technology development; project; information; and investing services, as well as the import and export of pharmaceutical products. The company has license agreement with GSK plc to develop up to 12 innovative medicines in respiratory, immunology and inflammation, and oncology areas.
1.410 T
01276.HKMarket value -Rank by Market Cap -/-

Financial Score

08/11/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking1/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE14.46%A
    • Profit Margin24.10%A
    • Gross Margin85.58%A
  • Growth ScoreB
    • Revenue YoY17.97%B
    • Net Profit YoY35.67%B
    • Total Assets YoY39.40%A
    • Net Assets YoY33.55%A
  • Cash ScoreB
    • Cash Flow Margin414.88%C
    • OCF YoY17.97%B
  • Operating ScoreC
    • Turnover0.53C
  • Debt ScoreA
    • Gearing Ratio12.14%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    "Large Transactions" Hengrui Pharma had a cross trade of approximately 360,000 shares, involving a capital of 25.83 million yuan

    According to a report from Economic Information Daily on the 6th, Hengrui Pharma recorded a cross-trade of 359,600 shares at 10:43 am, with each share priced at HKD 71.825, down 0.7% from the previous closing price, involving a total of HKD 25.83 million. Hengrui Pharma's current price is down 0.6%, at HKD 71.85; trading volume is 951,400 shares, with a transaction amount of HKD 68.26 million, and the active buy-sell ratio is 55:45, with a net active buying of HKD 4.4926 million. (rw)

    etnet·
    SH
    600276
    -1.35%
    HK
    01276
    -3.45%
    etnet·
    SH
    600276
    -1.35%
    HK
    01276
    -3.45%

    "Large Transactions" Hengrui Pharma had a cross-trade of approximately 280,000 shares, involving a capital of 20.39 million yuan

    According to the Economic News Agency on the 4th, Hengrui Pharma recorded a cross trade of 280,800 shares at 1:00 PM, with each share priced at HKD 72.625, down 1.9% from the previous closing price, involving a total of HKD 20.39 million. Hengrui Pharma's current price is down 1.9%, reported at HKD 72.6; trading volume is 2.1739 million shares, with a transaction amount of HKD 158 million, and the active buy-sell ratio is 73:27, with a net active buying of HKD 50.89 million. (rw)

    etnet·
    SH
    600276
    -1.35%
    HK
    01276
    -3.45%
    etnet·
    SH
    600276
    -1.35%
    HK
    01276
    -3.45%

    Hengrui Pharma repurchased 7.9188 million A shares for a total amount of 535 million RMB

    Hengrui Pharma announced that as of October 31, it repurchased 7.9188 million A shares through centralized bidding, accounting for 0.12% of the total share capital; the price per share ranged from RMB 62.9 to 70, with a total amount of approximately RMB 535 million

    AASTOCKS·
    SH
    600276
    -1.35%
    HK
    01276
    -3.45%
    AASTOCKS·
    SH
    600276
    -1.35%
    HK
    01276
    -3.45%
    Posts
    View More